1-3 of 3
J. Fred Kolhouse, MD
Close
Sort by
Journal Articles

Presence of Dysregulated Immune Recovery (IMD) Following Autotransplant May Change the Type of Predominant Serum Light Chain and Elevate the Level in Patients with Multiple Myeloma (MM).

Choon Kee Lee, MD, Mary Berg, MD, John Ryder, Han Myint, FRCP, FRCPath, J. Fred Kolhouse, MD, William Robinson, MD
Journal: Blood
Blood (2009) 114 (22): 4870.
https://doi.org/10.1182/blood.V114.22.4870.4870
Published: 2009
Journal Articles

Unremitting Presence of Marrow Immunoglobulin Heavy Chain Gene Rearrangement (IGH-GR) 3 Months Following Autotransplant Is Associated with Poor Outcome in Disease Control in Patients with Multiple Myeloma (MM).

Choon Kee Lee, MD, Qi Wei, Director, Laboratory, Develpment, Molecular, Diagnostics, Mark Lovell, Associate, Professor, Karen Swisshelm, Co-Director, John Ryder, Han Myint, FRCP, FRCPath, J. Fred Kolhouse, MD, William Robinson, MD
Journal: Blood
Blood (2009) 114 (22): 1807.
https://doi.org/10.1182/blood.V114.22.1807.1807
Published: 2009
Journal Articles

An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide.

Choon Kee Lee, MD, Jeff Kaiser, Pharm., D., Han Myint, FRCP, FRCPath, Mary Berg, MD, J. Fred Kolhouse, MD, William Robinson, MD
Journal: Blood
Blood (2009) 114 (22): 3404.
https://doi.org/10.1182/blood.V114.22.3404.3404
Published: 2009